secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-08-14T19:00:21+00:00
Accession:  0001493152-26-038240
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics non-reliance on Q1 2026 financials; EPS overstated by $0.80
-------------------------------------------------------------------------

- Audit Committee concluded Aug 10, 2026 that Q1 2026 financials in Form 10-Q (filed May 14, 2026) should no longer be relied upon.
- EPS overstated by $0.80: reported $2.19 basic/diluted; correct two-class allocation is 63.3% to common, 36.7% to participating securities.
- As of Mar 31, 2026: 904,312 weighted-average common shares; 524,501 shares from participating warrants outstanding.
- Material weakness in internal control over financial reporting: ineffective technical accounting review of complex warrant instruments.
- Company will file Form 10-Q/A and amend registration statements; remediation measures include enhanced technical accounting review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226038240/0001493152-26-038240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226038240/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer